Abstract
Rheumatoid arthritis (RA) is a systemic, inflammatory, autoimmune disorder with progressive articular damage that may result in lifelong disability. Although major strides in understanding the disease have been made, the pathogenesis of RA has not yet been fully elucidated. Early treatment can prevent severe disability and lead to remarkable patient benefits, although a lack of therapeutic efficiency in a considerable number of patients remains problematic.
MicroRNAs (miRNAs) are small, non-coding RNAs that, depending upon base pairing to messenger RNA (mRNA), mediate mRNA cleavage, translational repression or mRNA destabilization. As fine tuning regulators of gene expression, miRNAs are involved in crucial cellular processes and their dysregulation has been described in many cell types in different diseases. In body fluids, miRNAs are present in microvesicles or incorporated into complexes with Argonaute 2 (Ago 2) or high-density lipoproteins and show high stability. Therefore, they are of interest as potential biomarkers of disease in daily diagnostic applications. Targeting miRNAs by gain or loss of function approaches have brought therapeutic effects in various animal models.
Over the past several years it has become clear that alterations exist in the expression of miRNAs in patients with RA. Increasing numbers of studies have shown that dysregulation of miRNAs in peripheral blood mononuclear cells or isolated T lymphocytes, in synovial tissue and synovial fibroblasts that are considered key effector cells in joint destruction, contributes to inflammation, degradation of extracellular matrix and invasive behaviour of resident cells. Thereby, miRNAs maintain the pathophysiological process typical of RA.
The aim of the current review is to discuss the available evidence linking the expression of miRNAs to inflammatory and immune response in RA and their potential as biomarkers and the novel targets for treatment in patients with RA.
Similar content being viewed by others
References
Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009 Feb 21; 373 (9664): 659–72
Müller-Ladner U, Pap T, Gay RE, et al. Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat Clin Pract Rheumatol 2005 Dec; 1 (2): 102–10
McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007 Jun; 7 (6): 429–42
Ospelt C, Gay S. The role of resident synovial cells in destructive arthritis. Best Pract Res Clin Rheumatol 2008 Apr; 22 (2): 239–52
Karouzakis E, Neidhart M, Gay RE, et al. Molecular and cellular basis of rheumatoid joint destruction. Immunol Lett 2006 Jul 15; 106(1): 8–13
Müller-Ladner U, Kriegsmann J, Franklin BN, et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 1996 Nov; 149 (5): 1607–15
Lefèvre S, Knedla A, Tennie C, et al. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med 2009 Dec; 15 (12): 1414–20
Karouzakis E, Gay RE, Gay S, et al. Epigenetic control in rheumatoid arthritis synovial fibroblasts. Nat Rev Rheumatol 2009 May; 5 (5): 266–72
Jüngel A, Ospelt C, Gay S. What can we learn from epigenetics in the year 2009? Curr Opin Rheumatol 2010 May; 22 (3): 284–92
Trenkmann M, Brock M, Ospelt C, et al. Epigenetics in rheumatoid arthritis. Clin Rev Allergy Immunol 2010 Aug; 39 (1): 10–9
Luo X, Tsai LM, Shen N, et al. Evidence for microRNA-mediated regulation in rheumatic diseases. Ann Rheum Dis 2010 Jan; 69 Suppl. 1: i30–6
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004 Jan 23; 116 (2): 281–97
Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 2009 Feb; 10 (2): 126–39
Kawamata T, Tomari Y. Making RISC. Trends Biochem Sci 2010 Jul; 35 (7): 368–76
Kwak PB, Tomari Y. The N domain of Argonaute drives duplex unwinding during RISC assembly. Nat Struct Mol Biol 2012; 19 (2): 145–51
Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of posttranscriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008 Feb; 9 (2): 102–14
Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5’ UTR as in the 3′ UTR. Proc Natl Acad Sci USA 2007 Jun 5; 104 (23): 9667–72
Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005 Jan 14; 120 (1): 15–20
Kloosterman WP, Wienholds E, Ketting RF, et al. Substrate requirements for let-7 function in the developing zebrafish embryo. Nucleic Acids Res 2004 Dec 7; 32 (21): 6284–91
Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol 2007 Mar; 17 (3): 118–26
Wu L, Fan J, Belasco JG. MicroRNAs direct rapid deadenylation of mRNA. Proc Natl Acad Sci U S A 2006 Mar 14; 103 (11): 4034–9
Eulalio A, Huntzinger E, Nishihara T, et al. Deadenylation is a widespread effect of miRNA regulation. RNA 2009 Jan; 15 (1): 21–32
Behm-Ansmant I, Rehwinkel J, Doerks T, et al. mRNA degradation by miRNAs and GW182 requires both CCR4:NOT deadenylase and DCP1:DCP2 decapping complexes. Genes Dev 2006 Jul 15; 20 (14): 1885–98
Guo H, Ingolia NT, Weissman JS, et al. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010 Aug 12; 466 (7308): 835–40
Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007 Dec 21; 318 (5858): 1931–4
Westholm JO, Lai EC. Mirtrons: microRNA biogenesis via splicing. Biochimie 2011 Nov; 93 (11): 1897–904
Cifuentes D, Xue H, Taylor DW, et al. A novel miRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity. Science 2010 Jun 25; 328(5986): 1694–8
Cheloufi S, Dos Santos CO, Chong MM, et al. A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature 2010 Jun 3; 465(7298): 584–9
Okamura K, Phillips MD, Tyler DM, et al. The regulatory activity of microRNA * species has substantial influence on microRNA and 3′ UTR evolution. Nat Struct Mol Biol 2008 Apr; 15(4): 354–63
Guo L, Lu Z. The fate of miRNA* strand through evolutionary analysis: implication for degradation as merely carrier strand or potential regulatory molecule? PLoS One. 2010 Jun 30; 5(6): e1 1387
Yang JS, Phillips MD, Betel D, et al. Widespread regulatory activity of vertebrate microRNA* species. RNA 2011 Feb; 17(2): 312–26
Iorio MV, Piovan C, Croce CM. Interplay between microRNAs and the epigenetic machinery: an intricate network. Biochim Biophys Acta 2010 Oct–Dec; 1799(10–12): 694–701
Tili E, Michaille JJ, Costinean S, et al. MicroRNAs, the immune system and rheumatic disease. Nat Clin Pract Rheumatol 2008 Oct; 4(10): 534–41
Furer V, Greenberg JD, Attur M, et al. The role of microRNA in rheumatoid arthritis and other autoimmune diseases. Clin Immunol 2010 Jul; 136(1): 1–15
Duroux-Richard I, Presumey J, Courties G, et al. MicroRNAs as new player in rheumatoid arthritis. Joint Bone Spine 2011 Jan; 78(1): 17–22
Wittmann J, Jäck HM. microRNAs in rheumatoid arthritis: midget RNAs with a giant impact. Ann Rheum Dis 2011 Mar; 70 Suppl. 1: 192–6
Nakasa T, Nagata Y, Yamasaki K, et al. A mini-review: microRNA in arthritis. Physiol Genomics 2011 May 1; 43(10): 566–70
Ceribelli A, Yao B, Dominguez-Gutierrez PR, et al. MicroRNAs in systemic rheumatic diseases. Arthritis Res Ther 2011 Jul 13; 13(4): 229
Ceribelli A, Nahid MA, Satoh M, et al. MicroRNAs in rheumatoid arthritis. FEBS Lett 2011 Dec 1; 585(23): 3667–74
Duroux-Richard I, Jorgensen C, Apparailly F. What do microRNAs mean for rheumatoid arthritis? Arthritis Rheum 2012 Jan; 64(1): 11–20
Baxter D, McInnes IB, Kurowska-Stolarska M. Novel regulatory mechanisms in inflammatory arthritis: a role for microRNA. Immunol Cell Biol 2012 Mar; 90(3): 288–92
Stanczyk J, Pedrioli DM, Brentano F, et al. Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum 2008 Apr; 58(4): 1001–9
Kurowska-Stolarska M, Alivernini S, Ballantine LE, et al. MicroRNA-155as a proinflammatory regulator in clinical and experimental arthritis. Proc Natl Acad Sci U S A 2011 Jul 5; 108(27): 11193–8
Niimoto T, Nakasa T, Ishikawa M, et al. MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients. BMC Musculoskelet Disord 2010 Sep 15; 11: 209
Pauley KM, Satoh M, Chan AL, et al. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther 2008; 10(4): R101
Blüml S, Bonelli M, Niederreiter B, et al. Essential role of micro RNA-155 in the pathogenesis of autoimmune arthritis in mice. Arthritis Rheum 2011 May; 63(5): 1281–8
Vigorito E, Perks KL, Abreu-Goodger C, et al. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity 2007 Dec; 27(6): 847–59
O’Connell RM, Kahn D, Gibson WS, et al. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 2010 Oct 29; 33(4): 607–19
Mizoguchi F, Izu Y, Hayata T, et al. Osteoclast-specific Dicer gene deficiency suppresses osteoclastic bone resorption. J Cell Biochem 2010 Apr 1; 109(5): 866–75
O’Connell RM, Rao DS, Chaudhuri AA, et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 2008 Mar 17; 205(3): 585–94
Tili E, Michaille JJ, Cimino A, et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol 2007 Oct 15; 179(8): 5082–9
Ceppi M, Pereira PM, Dunand-Sauthier I, et al. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc Natl Acad Sci U S A 2009 Feb 24; 106(8): 2735–40
Ma X, Becker Buscaglia LE, Barker JR, et al. MicroRNAs in NF-kappaB signaling. J Mol Cell Biol 2011 Jun; 3(3): 159–66
Nakasa T, Miyaki S, Okubo A, et al. Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum 2008 May; 58(5): 1284–92
Li J, Wan Y, Guo Q, et al. Altered microRNA expression profile with miR-146a upregulation in CD4+ T cells from patients with rheumatoid arthritis. Arthritis Res Ther 2010; 12(3): R81
Taganov KD, Boldin MP, Chang KJ, et al. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A 2006 Aug 15; 103(33): 12481–6
Yamasaki K, Nakasa T, Miyaki S, et al. Expression of MicroRNA-146a in osteoarthritis cartilage. Arthritis Rheum 2009 Apr; 60(4): 1035–41
Curtale G, Citarella F, Carissimi C, et al. An emerging player in the adaptive immune response: microRNA-146a is a modulator of IL-2 expression and activation-induced cell death in T lymphocytes. Blood 2010 Jan 14; 115(2): 265–73
Pap T, Franz JK, Hummel KM, et al. Activation of synovial fibroblasts in rheumatoid arthritis: lack of expression of the tumour suppressor PTEN at sites of invasive growth and destruction. Arthritis Res 2000; 2(1): 59–64
Salmon M, Scheel-Toellner D, Huissoon AP, et al. Inhibition of T cell apoptosis in the rheumatoid synovium. J Clin Invest 1997 Feb 1; 99(3): 439–46
Cantwell MJ, Hua T, Zvaifler NJ, et al. Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis. Arthritis Rheum 1997 Sep; 40(9): 1644–52
Nakasa T, Shibuya H, Nagata Y, et al. The inhibitory effect of microRNA-146a expression on bone destruction in collagen-induced arthritis. Arthritis Rheum 2011 Jun; 63(6): 1582–90
Stanczyk J, Ospelt C, Karouzakis E, et al. Altered expression of miR-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. Arthritis Rheum 2011 Feb; 63(2): 373–81
Yu H, Lu J, Zuo L, et al. Epstein-Barr virus downregulates microRNA-203 through the oncoprotein latent membrane protein 1: a contribution to increased tumor incidence in epithelial cells. J Virol 2012 Mar; 86(6): 3088–99
Ru P, Steele R, Hsueh EC, et al. Anti-miR-203 upregulates SOCS3 expression in breast cancer cells and enhances cisplatin chemosensitivity. Genes Cancer 2011 Jul; 2(7): 720–7
Bueno MJ, Pérez de Castro I, Gómez de Cedrón M, et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 2008 Jun; 13(6): 496–506
Furuta M, Kozaki KI, Tanaka S, et al. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010 May; 31(5): 766–76
Viticchiè G, Lena AM, Latina A, et al. MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines. Cell Cycle 2011 Apr 1; 10(7): 1121–31
Greither T, Grochola LF, Udelnow A, et al. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer 2010 Jan 1; 126(1): 73–80
Nakamachi Y, Kawano S, Takenokuchi M, et al. MicroRNA-124a is a key regulator of proliferation and monocyte chemoattractant protein 1 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum 2009 May; 60(5): 1294–304
Koch AE, Kunkel SL, Harlow LA, et al. Enhanced production of monocyte chemoattractant protein 1 in rheumatoid arthritis. J Clin Invest 1992 Sep; 90(3): 772–9
Koch AE, Harlow LA, Haines GK, et al. Vascular endothelial growth factor: a cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994 Apr 15; 152(8): 4149–56
Akhavani MA, Madden L, Buysschaert I, et al. Hypoxia upregulates angiogenesis and synovial cell migration in rheumatoid arthritis. Arthritis Res Ther 2009; 11(3): R64
Kawano S, Nakamachi Y. miR-124a as a key regulator of proliferation and MCP-1 secretion in synoviocytes from patients with rheumatoid arthritis. Ann Rheum Dis 2011 Mar; 70 Suppl. 1: 188–91
Lujambio A, Ropero S, Ballestar E, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007 Feb 15; 67(4): 1424–9
Fulci V, Scappucci G, Sebastiani GD, et al. miR-223 is overexpressed in T-lymphocytes of patients affected by rheumatoid arthritis. Hum Immunol 2010 Feb; 71(2): 206–11
Nagata Y, Nakasa T, Mochizuki Y, et al. Induction of apoptosis in the synovium of mice with autoantibody-mediated arthritis by the intraarticular injection of double-stranded MicroRNA-15a. Arthritis Rheum 2009 Sep; 60(9): 2677–83
Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005 Sep 27; 102(39): 13944–9
Alsaleh G, Suffert G, Semaan N, et al. Bruton’s tyrosine kinase is involved in miR-346-related regulation of IL-18 release by lipopolysaccharide-activated rheumatoid fibroblast-like synoviocytes. J Immunol 2009 Apr 15; 182(8): 5088–97
Horwood NJ, Mahon T, McDaid JP, et al. Epigenetic control in rheumatoid arthritis synovial fibroblasts. Bruton’s tyrosine kinase is required for lipopolysaccharide-induced tumor necrosis factor alpha production. J Exp Med 2003 Jun 16; 197(12): 1603–11
Semaan N, Frenzel L, Alsaleh G, et al. miR-346 controls release of TNF-α protein and stability of its mRNA in rheumatoid arthritis via tristetraprolin stabilization. PLoS ONE 2011; 6(5): e19827
Niederer F, Trenkmann M, Ospelt C, et al. Downregulation of microRNA-34a* in rheumatoid arthritis synovial fibroblasts promotes apoptosis resistance. Arthritis Rheum Epub 2011 Dec 12
Iliopoulos D, Malizos KN, Oikonomou P, et al. Integrative microRNA and proteomic approaches identify novel osteoarthritis genes and their collaborative metabolic and inflammatory networks. PLoS ONE 2008; 3(11): e3740
Jones SW, Watkins G, Le Good N, et al. The identification of differentially expressed microRNA in osteoarthritic tissue that modulate the production of TNF-alpha and MMP13. Osteoarthritis Cartilage 2009 Apr; 17(4): 464–72
Abouheif MM, Nakasa T, Shibuya H, et al. Silencing microRNA-34a inhibits chondrocyte apoptosis in a rat osteoarthritis model in vitro. Rheumatology (Oxford) 2010 Nov; 49(11): 2054–60
Miyaki S, Nakasa T, Otsuki S, et al. MicroRNA-140 is expressed in differ-entiated human articular chondrocytes and modulates interleukin-1 responses. Arthritis Rheum 2009 Sep; 60(9): 2723–30
Miyaki S, Sato T, Inoue A, et al. MicroRNA-140 plays dual roles in both cartilage development and homeostasis. Genes Dev 2010 Jun 1; 24(11): 1173–85
Tardif G, Hum D, Pelletier JP, et al. Regulation of the IGFBP-5 and MMP-13 genes by the microRNAs miR-140 and miR-27a in human osteoarthritic chondrocytes. BMC Musculoskelet Disord 2009 Nov 30; 10: 148
Liang Y, Ridzon D, Wong L, et al. Characterization of microRNA expression profiles in normal human tissues. BMC Genomics 2007 Jun 12; 8: 166
Gaur A, Jewell DA, Liang Y, et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 2007 Mar 15; 67(6): 2456–68
Zen K, Zhang CY. Circulating MicroRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 2012 Mar; 32(2): 326–48
Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008 Jul 29; 105(30): 10513–8
Hunter MP, Ismail N, Zhang X, et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE 2008; 3(11): e3694
Iguchi H, Kosaka N, Ochiya T. Secretory microRNAs as a versatile communication tool. Commun Integr Biol 2010 Sep; 3(5): 478–81
Kosaka N, Iguchi H, Yoshioka Y, et al. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem 2010 Jun 4; 285(23): 17442–52
Valadi H, Ekström K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007 Jun; 9(6): 654–9
Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 2011 Mar 22; 108(12): 5003–8
Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011 Apr; 13(4): 423–33
Wang K, Zhang S, Weber J, et al. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res 2010 Nov; 38(20): 7248–59
Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. PLoS ONE 2008 Sep 5; 3(9): e3148
Pigati L, Yaddanapudi SC, Iyengar R, et al. Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS ONE 2010 Oct 20; 5(10):e13515
Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008 Oct; 18(10): 997–1006
Wang JF, Yu ML, Yu G, et al. Serum miR-146a and miR-223 as potential new biomarkers for sepsis. Biochem Biophys Res Commun 2010 Mar 26; 394(1): 184–8
Murata K, Yoshitomi H, Tanida S, et al. Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 2010; 12(3): R86
Alevizos I, Illei GG. MicroRNAs as biomarkers in rheumatic diseases. Nat Rev Rheumatol 2010 Jul; 6(7): 391–8
Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet 2007 Dec 1; 370(9602): 1861–74
Senolt L, Vencovský J, Pavelka K, et al. Prospective new biological therapies for rheumatoid arthritis. Autoimmun Rev 2009 Dec; 9(2): 102–7
Wang V, Wu W. MicroRNA-based therapeutics for cancer. BioDrugs 2009; 23(1): 15–23
McDermott AM, Heneghan HM, Miller N, et al. The therapeutic potential of microRNAs: disease modulators and drug targets. Pharm Res 2011 Dec; 28(12): 3016–29
Kim M, Kasinski AL, Slack FJ. MicroRNA therapeutics in preclinical cancer models. Lancet Oncol 2011 Apr; 12(4): 319–21
Nana-Sinkam SP, Croce CM. MicroRNAs as therapeutic targets in cancer. Transl Res 2011 Apr; 157(4): 216–25
Rossbach M. Small non-coding RNAs as novel therapeutics. Curr Mol Med 2010 Jun; 10(4): 361–8
Weiler J, Hunziker J, Hall J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Gene Ther 2006 Mar; 13(6): 496–502
Wahlestedt C, Salmi P, Good L, et al. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci U S A 2000 May 9; 97(10): 5633–8
Krützfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with ‘antagomir’. Nature 2005 Dec 1; 438(7068): 685–9
Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010 Jan 8; 327(5962): 198–201
Santaris Pharma A/S. Multiple ascending dose study of miravirsen in treatment-naïve chronic hepatitis C subjects [ClinicalTrials.gov identifier NCT01200420]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Mar 20]
Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007 Sep; 4(9): 721–6
Wang Z. The principles of MiRNA-masking antisense oligonucleotides technology. Methods Mol Biol 2011; 676: 43–9
Ma L, Young J, Prabhala H, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010 Mar; 12(3): 247–56
Choi WY, Giraldez AJ, Schier AF. Target protectors reveal dampening and balancing of Nodal agonist and antagonist by miR-430. Science 2007 Oct 12; 318(5848): 271–4
Li C, Feng Y, Coukos G, et al. Therapeutic micro RNA strategies in human cancer. AAPS J 2009 Dec; 11(4): 747–57
Chen Y, Zhu X, Zhang X, et al. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther 2010 Sep; 18(9): 1650–6
Wolfrum C, Shi S, Jayaprakash KN, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 2007 Oct; 25(10): 1149–57
Simeoni F, Morris MC, Heitz F, et al. Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res 2003 Jun 1; 31(11): 2717–24
Minakuchi Y, Takeshita F, Kosaka N, et al. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res 2004 Jul 22; 32(13): e109
Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular micro RNA/short hairpin RNA pathways. Nature 2006 May 25; 441(7092): 537–41
Kota J, Chivukula RR, O’Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009 Jun 12; 137(6): 1005–17
Nasser MW, Datta J, Nuovo G, et al. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem 2008 Nov 28; 283(48): 33394–405
Kong W, He L, Coppola M, et al. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem 2010 Jun 4; 285(23): 17869–79
Ferracin M, Zagatti B, Rizzotto L, et al. MicroRNAs involvement in fludara-bine refractory chronic lymphocytic leukemia. Mol Cancer 2010 May 26; 9:123
Blower PE, Chung JH, Verducci JS, et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 2008 Jan; 7(1): 1–9
Acknowledgements
This work was supported by IAR-EPALINGES, FP7 Masterswitch and ARTICULUM fellowship. The authors have no conflicts of interest that are directly relevant to the content of this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Filková, M., Jüngel, A., Gay, R.E. et al. MicroRNAs in Rheumatoid Arthritis. BioDrugs 26, 131–141 (2012). https://doi.org/10.2165/11631480-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11631480-000000000-00000